Prot #REMPEX-506: A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE

Project: Research project

Project Details

StatusFinished
Effective start/end date7/7/14 → 7/7/20

Funding

  • Rempex Pharmaceuticals, Inc. (Prot #REMPEX-506)